Phaseline

Targets › ENME

ENME: drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 4; Hematology, Infectious disease; next expected readout May 2029.

Open in Phaseline: the race on ENME, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Orchid Pharma EuropeCefepime
Bacterial penicillin-binding protein inhibitor
CEPE, ENMEPhase 2Complicated Urinary Tract Infection; Infection; Intestinal MicrobiomeMay 2029

Conditions

Complicated Urinary Tract Infection (1) Infection (1) Intestinal Microbiome (1)

Modalities

small molecule (1)

Companies

Orchid Pharma Europe (1)

Related targets

CEPE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.